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Donor Derived Systemic Lupus Erythematosus (SLE) after
Allogeneic Transplantation
Dhivya Sugumar 1, Jack Lionberger 2, Mark Fesler 3,
Rama Bandlamudi 4, Sagun D. Goyal 3. 1 Internal Medicine,
St. Mary’s Health Center, St. Louis, MO; 2Hematology -
Oncology, St. Louis University, St. Louis, MO; 3Hematology/
Oncology, Saint Louis University, St. Louis, MO; 4 Rheumatology,
St. Louis University, St. Louis, MO
Donor-related autoimmune diseases after hematopoietic cell
transplantation (HCT) are not well characterized. Most post-
transplant immune disorders come in the guise of GVHD or
reactions by the recipient to therapy (pneumonitis). The
extreme minority are due to donor-related adoptive immu-
nity. It is interesting that donor-derived auto-immune issues
are not more common after HCT, suggesting the presence of
identiﬁable risk factors.
A 30-year-old male underwent myeloablative matched
related allogeneic peripheral blood stem cell transplant for
Philadelphia chromosome positive Acute Lymphoid Leuke-
mia (ALL). Importantly, the patient did not have any history
of rheumatologic disorders, and speciﬁcally no history of
Systemic Lupus Erythematosus (SLE). On D+10 he developed
chest pain; echocardiogram showed a moderate pericardial
effusion that resolved with NSAIDs therapy. He later (D+73)
developed myalgia and poly-synovitis requiring signiﬁcant
doses of opioids for relief. Infectious work-up was negative.
Autoimmune evaluation demonstrated anti-nuclear anti-
bodies (ANA) with elevated anti-double stranded DNA (477U
(range 0e29U)) as well as anti-smooth muscle antibody (SM
Ab e 77 U (0-19.9)). SLE diagnosis was made by Rheuma-
tology and the patient was started on hydroxy-chloroquine,
celecoxib and prednisone. The patient responded and is
currently on maintenance therapy. In retrospect, donor his-
tory was notable for chronic pain and labs showed a mild
eosinophilia with an absolute eosinophil count of 530/ml.
Signiﬁcantly, the donor was subsequently tested and diag-
nosed with SLE as well.
Donor screening for auto-immune diseases could be
considered in those with suspicious ﬁndings on evaluation.
This case demonstrates a real threat to recipient morbidity
after HCT due to a donor-related immune issue. Further
study is needed to understand the incidence, severity and
pattern of autoimmune diseases after HCT.AUTOLOGOUS TRANSPLANTS137
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Purpose: To review the outcomes of refractory and relapsed
Hodgkin’s Lymphoma in pediatric patients treated with high
dose chemotherapy (HDC) followed by autologous stem cell
transplantation (ASCT) at a single center.
Materials and Methods: All patients, up to the age of 18
years, with refractory or relapsed Hodgkin’s Lymphomawho
had complete or good-partial response to salvage chemo-
therapy were included in the study. All received HDC and
ASCT during October 2010 to June 2014. Medical records of
these patients were reviewed. The following variables were
collected in addition to demographics and stage of disease at
the time of relapse.
Time to engraftment from the day of stem cells re-
infusion
Radiological response assessed by PET-CT at day-60 after
stem cell re-infusion and
Disease free interval till the last follow-up
Results: Nineteen patients were studied, 15 were male.
Median age at relapse was 13 years (range 4-18 years). At the
time of relapse, 10 patients had stage IV disease, 6 had stage
III and two of stage II and one of Stage I. Median time to
engraftment was 13 days (range 10-21 days). Complete
metabolic remissionwas demonstrated in all 19 cases on FDG
PET/CT scan on day-60. Two patients had signiﬁcant
morphological residual disease requiring involved ﬁeld ra-
diation therapy. All but one patient remained disease free for
the duration of follow-up (median 16 months, range 3- >44
months). Disease free survival (DFS) was 92% during this
follow-up period. One patient had disease progression at 7
months post ASCT.
Conclusion: HDC(BEAM) followed by ASCT appears an
effective treatment strategy for relapsed or refractory pedi-
atric Hodgkin’s Lymphoma who had complete or good-par-
tial response to salvage chemotherapy, in our single center
experience during our short term follow-up. Long term
follow-up is suggested to evaluate disease free and overall
survival beneﬁts.
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Background: High-dose melphalan followed by autologous
stem cell rescue has been shown to signiﬁcantly increase
progression free survival and overall survival in patients with
multiple myeloma. Renal failure (RF) often precludes patient
enrollment in studies involving high-dose mephalan condi-
tioning for autologous stem cell transplant (ASCT) due to
increased treatment-related morbidity and mortality. How-
ever, several studies have shown that RF should not be an
exclusion criterion and early ASCT could be helpful in
